ロード中...
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab
OBJECTIVE: To analyze the spectrum and mechanisms of cutaneous adverse events (AEs) in patients with multiple sclerosis treated with daclizumab high-yield process (DAC-HYP). METHODS: A total of 31 participants in an institutional review board–approved open-label phase I study of DAC-HYP (NCT01143441...
保存先:
| 出版年: | Neurology |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4793779/ https://ncbi.nlm.nih.gov/pubmed/26843560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000002417 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|